vIRA Inhibition of Antiviral Necroptosis and RIPK3 Binding Are Separable Events
Pathogens · 2026
DOI: 10.3390/pathogens15010079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2026. Verfasst von Katherine B Ragan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biosciences, Institute for Cellular and Molecular Biology, LaMontagne Center for Infectious Disease, University of Texas at A…. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Necroptosis, Viral Proteins, Muromegalovirus. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Prevention and Research Institute of Texas, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Necroptosis is an antiviral form of programmed cell death modulated by proteins that interact via RIP Homotypic Interaction Motifs (RHIMs). The result of the signaling pathways depends on which RHIM-containing proteins are involved: although both host and viral proteins contain RHIMs, virally encoded RHIM proteins, such as murine cytomegalovirus (MCMV)-encoded viral inhibitor of RIP activation (vIRA) serve to prevent cell death. Although every RHIM contains the same core four-amino-acid pattern, there are variations in individual sequences that we hypothesized would determine the differential outcomes in necroptotic signaling. As such, we replaced the RHIM in vIRA with the RHIMs from other proteins involved in the signaling cascade (RIPK1, RIPK3, ZBP1, ICP6) to assess the effect on necroptosis during MCMV infection. Although these RHIM-swap vIRA constructs remained able to bind to RIPK3, in the context of MCMV infection, they lost the ability to prevent necroptosis. These results are consistent with other studies that demonstrate that RHIM-containing proteins form amyloid fibrils unique to the proteins interfacing. Our results provide biological context for the growing model that the outcome of RHIM-based signaling is influenced by the specific amyloid fibril structures that are driven by the unique amino-acid sequences of each RHIM present.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biosciences, Institute for Cellular and Molecular Biology, LaMontagne Center for Infectious Disease, University of Texas at Austin, Austin, TX 78712, USA.
- Independent Researcher, Atlanta, GA 30317, USA.
- Thermo Fisher Scientific, Whitefield, Bangalore 560066, India.
- Department of Biological Sciences, Auburn University, Auburn, AL 36849, USA.
- Independent Researcher, New Braunfels, TX 78130, USA.
- Independent Researcher, Austin, TX 78724, USA.
ORCID-Profile: Amanda D Fisher, Olivia N Brahms, Jason W Upton
Förderung
- Cancer Prevention and Research Institute of Texas
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- Auburn University institutional funds
Zitieren
APA
Ragan, K. B., Sridharan, H., Stark, A. S., Ilami, K., Fisher, A. D., Brahms, O. N., Kaiser, W. J., & Upton, J. W. (2026). vIRA Inhibition of Antiviral Necroptosis and RIPK3 Binding Are Separable Events. Pathogens. https://doi.org/10.3390/pathogens15010079
Vancouver
Ragan KB, Sridharan H, Stark AS, Ilami K, Fisher AD, Brahms ON, et al. vIRA Inhibition of Antiviral Necroptosis and RIPK3 Binding Are Separable Events. Pathogens. 2026. doi:10.3390/pathogens15010079
BibTeX
@article{Ragan2026,
author = {Ragan, Katherine B and Sridharan, Haripriya and Stark, Aaron S and Ilami, Kaela and Fisher, Amanda D and Brahms, Olivia N and Kaiser, William J and Upton, Jason W},
title = {vIRA Inhibition of Antiviral Necroptosis and RIPK3 Binding Are Separable Events},
journal = {Pathogens},
year = {2026},
doi = {10.3390/pathogens15010079}
}
EUVIMED